Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Tzouvelekis, Argyris
NCT05032066: A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis Jan 2024 - Dec 2024: Data from trial for diffuse cutaneous systemic sclerosis	Terminated	2	153	Europe, Canada, Japan, US, RoW	HZN-825, Placebo	Amgen	Idiopathic Pulmonary Fibrosis	07/24	01/25
NCT05082714: Tocilizumab Versus Baricitinib in Patients With Severe COVID-19	Completed	N/A	251	Europe	Tocilizumab, Baricitinib	University Hospital of Patras	COVID-19	06/22	06/22
Karampitsakos, Theodoros
NCT05082714: Tocilizumab Versus Baricitinib in Patients With Severe COVID-19	Completed	N/A	251	Europe	Tocilizumab, Baricitinib	University Hospital of Patras	COVID-19	06/22	06/22